- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01660854
Re-exposure of Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites (TIP4)
Re-exposure of Previously Immunized and Challenged Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites
In a previous study (NL33904.091.10) the investigators challenged 24 volunteers after Chloroquine Prophylaxis Sporozoites (CPS) immunization with 45, 30 or 15 infected mosquito-bites respectively. The availability of this immunized cohort opens the unique opportunity to determine protection to a heterologous challenge for both of the protected and unprotected volunteers as the previous challenge infection might have served as immunological boost to the unprotected volunteers.
In the current observational, proof of principle study, the investigators aim to investigate the protection on an individual basis of these previously immunized and challenged volunteers against a heterologous P. falciparum challenge.
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Leiden, 네덜란드, 2333ZA
- Leiden University Medical Centre
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age ≥ 18 and ≤ 35 years healthy volunteers (males or females)
- Good health based on history and clinical examination
- Negative pregnancy test
- Use of adequate contraception for females
- Signing of the informed consent form, thereby demonstrating understanding of the meaning and procedures of the study
- Agreement to inform the general practitioner and to sign a request to release medical information concerning contra-indications for participation in the study
- Willingness to undergo a Pf controlled challenge through mosquito bites
- Agreement to stay in a hotel room close to the trial centre during a part of the study (Day 5 after challenge till treatment is finished)
- Reachable (24/7) by mobile phone during the whole study period
- Available to attend all study visit
- Agreement to refrain from blood donation to Sanquin or for other purposes, during the whole study period
- Willingness to undergo HIV, hepatitis B and hepatitis C tests
- Negative urine toxicology screening test at screening visit and the day before challenge
- Willingness to take a curative regimen of Malarone®
Exclusion Criteria:
- History of malaria (other than participation in ZonMw1 study) or residence in malaria endemic areas within the past six months
- Plans to travel to malaria endemic areas during the study period
- Plans to travel outside of the Netherlands during the challenge period
- Previous participation in any malaria vaccine study and/or positive serology for Pf (except ZonMw1 volunteers)
- Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers
- History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)
- History of arrhythmias or prolonged QT-interval
- Positive family history in 1st and 2nd degree relatives for cardiac events < 50 years old
- An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system
- Clinically significant abnormalities in electrocardiogram (ECG) at screening
- Body Mass Index (BMI) below 18 or above 30 kg/m2
- Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis
- Positive HIV, HBV or HCV tests
- Participation in any other clinical study within 30 days prior to the onset of the study
- Enrollment in any other clinical study during the study period
- For women: being pregnant or lactating
- Volunteers unable to give written informed consent
- Volunteers unable to be closely followed for social, geographic or psychological reasons
- History of drug or alcohol abuse interfering with normal social function
- A history of treatment for psychiatric disease
- A history of convulsions
- Contra-indications to Malarone®, including hypersensitivity or treatment taken by the volunteer that interferes with Malarone®
- The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study onset (inhaled and topical corticosteroids and oral anti-histaminic are allowed) and during the study period
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including (functional) asplenia
- Co-workers or trainees of the departments Infectious Diseases, Medical Microbiology or Parasitology of the Leiden University Medical Centre (LUMC) or Medical Microbiology, Parasitology, Radboud University Nijmegen (RUNMC)
- A history of sickle cell anaemia, sickle cell trait, thalassaemia (or trait), G6PD deficiency
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Heterologous challenge
Biological: Heterologous challenge with 5 infected mosquito bites (NF135) after previous CPS immunization and challenge. Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone. Other Name: atovaquone/proguanil |
challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
Three days: 4 tablets 250/100mg per day
다른 이름들:
|
활성 비교기: Challenge control
Biological: Plasmodium falciparum mosquito challenge by the bites of 5 Plasmodium falciparum infected mosquitoes (NF135). Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone. Other Name: atovaquone/proguanil |
challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
Three days: 4 tablets 250/100mg per day
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Duration of prepatent period after challenge infection as measured by microscopy
기간: 21 days after challenge
|
21 days after challenge
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
연구 그룹의 징후 또는 증상의 빈도
기간: 챌린지 21일 후
|
챌린지 21일 후
|
• Parasitemia and kinetics of parasitemia as measured by PCR
기간: 21 days after challenge
|
21 days after challenge
|
• Immune responses between study groups
기간: 21 days after challenge
|
21 days after challenge
|
공동 작업자 및 조사자
수사관
- 연구 책임자: RW Sauerwein, PhD, Radboud University Medical Center
간행물 및 유용한 링크
일반 간행물
- Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, Renia L, van der Ven A, Hermsen CC, Sauerwein R. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009 Jul 30;361(5):468-77. doi: 10.1056/NEJMoa0805832.
- Schats R, Bijker EM, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, van Lieshout L, Haks MC, Hermsen CC, Scholzen A, Visser LG, Sauerwein RW. Heterologous Protection against Malaria after Immunization with Plasmodium falciparum Sporozoites. PLoS One. 2015 May 1;10(5):e0124243. doi: 10.1371/journal.pone.0124243. eCollection 2015.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
말라리아, 팔시파룸에 대한 임상 시험
-
Novartis Pharmaceuticals모병복잡하지 않은 Plasmodium Falciparum 말라리아코트디부아르, 케냐, 가나, 우간다
-
Medicines for Malaria Venture완전한복잡하지 않은 Plasmodium Falciparum 말라리아우간다, 베냉, 부키 나 파소, 콩고 민주 공화국, 가봉, 모잠비크, 베트남
-
Karolinska University HospitalMuhimbili University of Health and Allied Sciences완전한
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Medical Research...모병
-
Jomaa Pharma GmbHCentre de Recherche Médicale de Lambaréné알려지지 않은단순 급성 Plasmodium Falciparum 말라리아의 경구 치료
-
Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.PATH; World Health Organization; Xinhua Hospital, Shanghai Jiao Tong University School of... 그리고 다른 협력자들완전한
-
Muhimbili University of Health and Allied SciencesUppsala University; The Swedish Research Council아직 모집하지 않음
-
Novartis PharmaceuticalsEuropean and Developing Countries Clinical Trials Partnership (EDCTP)모병복잡하지 않은 Plasmodium Falciparum 말라리아부키 나 파소, 말리, 가봉
-
David SaundersNational Centre for Parasitology, Entomology and Malaria Control, Cambodia; Royal Cambodian... 그리고 다른 협력자들정지된
-
University of Oxford아직 모집하지 않음복잡하지 않은 Plasmodium Falciparum 말라리아
Heterologous challenge에 대한 임상 시험
-
National Institute of Allergy and Infectious Diseases...완전한
-
Johns Hopkins Bloomberg School of Public HealthUnited States Department of Defense; Naval Medical Research Center모집하지 않고 적극적으로
-
Malaria Vaccine and Drug Development CenterMinisterio de la Protección Social, Colombia.완전한